Reuters logo
BRIEF-Bristol-Myers Squibb receives positive CHMP opinion recommending opdivo
2017年3月24日 / 下午1点21分 / 6 个月前

BRIEF-Bristol-Myers Squibb receives positive CHMP opinion recommending opdivo

March 24 (Reuters) - Bristol-myers Squibb Co:

* Bristol-Myers Squibb receives positive chmp opinion recommending opdivo (nivolumab) for the treatment of squamous cell cancer of the head and neck in adults progressing on or after platinum-based therapy

* Bristol-Myers Squibb Co - positive opinion based on overall survival benefit demonstrated in phase 3 checkmate -141 trial

* Bristol-Myers Squibb Co- safety profile of opdivo in checkmate -141 was consistent with prior studies in other tumors

* Bristol-Myers Squibb - CHMP recommendation will now be reviewed by European Commission Source text for Eikon: Further company coverage:

我们的标准汤森路透“信任原则”
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below